1. Scrip
  2. >>Business
  3. >>Start-Ups & SMEs

Atriva: Targeting Patients, Not Virus, Is The Way Forward In Flu

 
• By John Davis

Emerging Company Profile: Four-year-old Atriva Therapeutics GmbH is developing a drug to prevent the proliferation of flu virus by transiently inhibiting one of the patient’s own cellular processes, a host-mediated novel mechanism of action that could be effective against a range of respiratory virus infections.

Emerging Company Profile Regular column feature image Version 2

The Tübingen, Germany-based biotech Atriva Therapeutics GMBH is aiming to move its host-targeting anti-flu MEK inhibitor, ATR-002, into initial clinical studies in 2019, and believes the molecule’s novel mode of action could offer advantages over other approaches in the treatment of influenza, including universal flu vaccines and next-generation virus-targeted small molecules.

The company, which boasts an experienced management team and serial entrepreneur Rainer Lichtenberger as CEO, also is attracting the interest...

Welcome to Scrip

Create an account to read this article

Already a subscriber?

More from Start-Ups & SMEs

Xoma On Its Royalty Model And Cleaning Up ‘Zombie’ Companies

 
• By Manas Mishra and Andrew McConaghie

Seizing an opportunity to buy out struggling 'zombie' biotechs, Xoma is helping to return investor cash and pick up potential bargain assets for itself. Its CEO and chief investment officer explained their approach to Scrip.

Maraganore, Meanwell Launch Corsera, Their Third Act In Cardiovascular Disease

 
• By Mandy Jackson

The biopharma industry veterans John Maraganore and Clive Meanwell partnered successfully twice before. With Corsera, the co-CEOs have raised more than $50m and aim to predict and prevent cardiovascular disease.

Lilly Obesity Deal Gives Superluminal More Shots On GPCR Goals

 
• By Andrew McConaghie

Superluminal’s CEO Cony D’Cruz believes its focus on GPCRs has already yielded a best-in-class obesity candidate for its own pipeline, as well as its $1bn- plus deal with Eli Lilly.

Norway’s Nykode Upbeat About Cancer Vaccines After Tough Year

 
• By Kevin Grogan

The firm is concentrating on its Keytruda combo for head and neck cancer after being abandoned by Roche and boardroom battles.

More from Business

Sanofi Shares Slide Despite Amlitelimab Eczema Win

 
• By Kevin Grogan

The OX40 ligand-targeting drug’s efficacy is seen as light compared with existing therapies.

Zydus Beats Gilead, Ipsen On Cholangitis Primary Endpoint But Pruritus Data Is Key

 
• By Vibha Ravi

Zydus's saroglitazar beat both Gilead’s Livdelzi and Ipsen’s Iqirvo on biochemical response in topline results from a Phase IIb/III trial in primary biliary cholangitis, but subtle differences in definitions, data on pruritus or itching and other factors could be key to approval and adoption.

Biogen Showcases Lupus Pipeline But Investors Will Have To Wait For Data

 
• By Jessica Merrill

R&D leaders highlighted two potential first-in-class assets during a therapeutic area overview, but regulatory filings remain years out.